- Advertisement -
- Advertisement -

Related

Positive Chain of Events for Norron

Latest Report

- Advertisement -

Stockholm (HedgeNordic) – Swedish biopharma BioArctic AB saw its share price increase by almost 50 percent on Tuesday after Biogen announced renewed plans to seek approval for its experimental Alzheimer’s drug, aducanumab, months after discontinuing clinical studies of the same drug. As the fifth-largest shareholder in BioArctic with a 3.5 percent stake, Stockholm-based asset manager Norron AB benefited from Biogen’s announcement, which raised the probability of success of BioArctic’s experimental drug for the treatment of Alzheimer’s disease.

The Swedish asset manager’s long-only equity fund Norron Active and market-neutral equity fund Norron Alpha are both invested in BioArctic AB. The long side of Norron Alpha, a member of the Nordic Hedge Index, constitutes a replica of Norron Active’s portfolio, with the hedge fund’s beta component reduced by shorting the OMX Stockholm Benchmark (SBX).

According to fund manager Gustaf Sjögren (pictured), who manages both Norron Alpha and Norron Active, “the positive development for aducanumab is a partial confirmation of the course of action for BioArctic’s BAN2401. Despite some differences, aducanumab and BAN2401 are relatively similar molecules.”

Biogen announced plans to seek approval from U.S. Food and Drug Administration (FDA) for the drug it abandoned earlier this year. In March, Biogen halted two Phase III clinical studies after the analysis of preliminary data available at the end of December of last year suggested aducanumab was destined for failure. A larger dataset with additional data from 2019 told a different story, as patients who received higher doses of aducanumab “experienced significant benefits on measures of cognition and function such as memory, orientation, and language,” the company reported.

“What happened is quite unusual in fact,” comments Sjögren in an interview with Finwire. “Biogen had previously withdrawn its application. Before Biogen’s announcement, the estimated probability of BioArctic to succeed was at 25 percent, now it is at maybe 45-50 percent, and I think you should have a higher probability.”

At the end of September, Norron AB owned 3.05 million shares of BioArctic, sitting as the fifth-largest shareholder after Pär Gellerfors and Lars Lannfelt, the two founders of BioArctic, as well as the Third and Fourth Swedish National Pension Funds (AP3 and AP4).

Subscribe to HedgeBrev, HedgeNordic’s weekly newsletter, and never miss the latest news!

Our newsletter is sent once a week, every Friday.

Eugeniu Guzun
Eugeniu Guzun
Eugeniu Guzun serves as a data analyst responsible for maintaining and gatekeeping the Nordic Hedge Index, and as a journalist covering the Nordic hedge fund industry for HedgeNordic. Eugeniu completed his Master’s degree at the Stockholm School of Economics in 2018. Write to Eugeniu Guzun at eugene@hedgenordic.com

Latest Articles

Active Decisions in Passive Wrappers: Othania on ETF Innovation

Founded in early 2016 by brothers Vincent Dilling-Larsen and Christian Mørup-Larsen, Danish fund boutique Othania built its foundation on a proprietary risk model, “Tiger,”...

Rettig Appoints Crescit Manager to Oversee Hedge Fund Strategies

Simon Borgefors has joined Finnish family-owned investment company Rettig as Investment Director for hedge fund strategies in Stockholm, leaving Swedish hedge fund boutique Crescit...

€5m Ticket to Nordic High Yield From German Family Office

A German family office plans an initial €5 million commitment to a UCITS‑compliant Nordic high‑yield fund, with capacity to scale over time. According to...

From Beef to Bitcoin: August’s Wild CTA Ride

In August 2025, the CTA sub-index of the Nordic Hedge Index edged lower after two positive months, reflecting mixed performance among managers. Strong gains...

Lauri Ehanti to Leave Aalto University Endowment After 14 Years

Lauri Ehanti is leaving Aalto University’s endowment fund after 14 years in various roles, most recently as Head of Investments. His responsibilities will be...

Othania’s All-In-One Fund Celebrates Five Years

Danish fund boutique Othania is celebrating the five-year anniversary of Othania Balanceret Makro, its all-in-one fund blending equity, bond, and alternatives exposure through Exchange...

Allocator Interviews

In-Depth: High Yield

Voices

Request for Proposal

- Advertisement -
HedgeNordic
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.